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a b s t r a c t
The most recent systematic review of randomized trials in patients with bone metastases has shown
equal efﬁcacy of single fraction (SF) and multiple fraction (MF) palliative radiation therapy in pain relief.
It is important to determine the patient population to which the evidence applies. This study aims to
examine the eligibility criteria of the studies included in the systematic review to deﬁne characteristics
of “uncomplicated” bone metastases.
Inclusion and exclusion criteria of 21 studies included in the systematic review were compared.
Common eligibility criteria were documented in hopes of deﬁning the speciﬁc features of a common
patient population representative of those in the studies.
More than half of the studies included patients with cytological or histological evidence of
malignancy. Patients with impending and/or existing pathological fracture, spinal cord compression or
cauda equina compression were excluded in most studies. Most studies also excluded patients receiving
retreatment to the same site.
“Uncomplicated” bone metastases can be deﬁned as: presence of painful bone metastases
unassociated with impending or existing pathologic fracture or existing spinal cord or cauda equina
compression. Therefore, MF and SF have equal efﬁcacy in patients with such bone metastases.
& 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Bone metastases are a common manifestation of cancer [1].
Most patients present with pain and impaired mobility, while
others can develop complications such as pathological fractures
and compression of the spinal cord or cauda equina [2]. Many
randomized studies have been conducted to determine if a dose
response exists for pain relief from palliative radiation therapy in
patients with painful bone metastases. The most recent systematic
review of these trials conclude the equivalency of single fraction
(SF) and multiple fraction (MF) treatments for pain relief from
“uncomplicated” bone metastases, though the meaning of the
term is not explicitly stated in most of the examined studies [3].
The United States national guidelines published by the Amer-
ican Society of Radiation Oncology and the American College of
Radiology suggest that there are no differences between SF and MF
dosing in palliative treatment for bone metastases [2,4], although
deﬁnitions distinguishing between complicated and uncompli-
cated bone metastases were not consistently provided. In practice,
most radiation oncologists consider bone metastases causing
pathologic fractures or compression of the spinal cord and cauda
equina to be complicated. Some also consider those with asso-
ciated soft tissue components or those within weight bearing
bones at high risk of fracture to be complicated as well, but
operational deﬁnitions vary among practice settings.
A clearer deﬁnition of “uncomplicated bone metastases” is
required to determine the patient population in which the results
of the prospective randomized trials apply. Whereas a workgroup
or committee could be established to explore this issue, the
translation of existing data to practice patterns necessitates a
comprehensive evaluation of the completed trials. So, the purpose
of the current study was to examine the inclusion and exclusion
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criteria of the randomized studies as described in the recent
systematic review [5–29], thereby clearly deﬁning the character-
istics of the patient population in which a SF is equivalent to MF
for the palliation of “uncomplicated” bone metastases.
2. Materials and methods
Only fully published trials from the systematic review were
included in the analysis, and therefore abstract by Kirkbride et al.
[13] was omitted. Study by Amouzegar-Hashemi et al. [24] and
abstract by Haddad et al. [29] used the same trial, and therefore
the former was used in the analysis. Study by Steenland et al. [26]
and follow-up by van der Linden et al. [18] used the same trial, and
therefore the former was used in the analysis. Study by Kaasa et al.
[28] and its follow-up by Sande et al. [27] also used the same trial,
and therefore the former was used in the analysis.
The methods sections of 21 studies comparing SF to MF course
of radiation therapy for painful bone metastases out of 25 studies
included in the most recent systematic review of bone metastases
treatment were examined by PMC, EW and NT for their patient
inclusion and exclusion criteria [5–29].
3. Results
The inclusion and exclusion criteria of the 21 studies are listed
in Table 1. All 21 studies included patients with bone metastases,
whereas all but one study speciﬁed painful bone metastases.
Thirteen of the 21 studies required cytological or histological
evidence of malignancy as part of the inclusion criteria, and 9 of
these studies required radiographic evidence of bone metastases.
Five of such studies did not specify the method of imaging,
1 speciﬁed X-ray, 2 speciﬁed X-ray or bone scan, and 1 speciﬁed
X-ray, bone scan, CT or MRI. Only 2 studies limited accrual to
patients with a previously speciﬁed primary tumor location, and
only 2 studies included patients with pain deemed to have
resulted from neuropathic pain.
Of the included 21 studies, 18 excluded patients with pathological
fracture, of which 12 studies excluded patients with existing patholo-
gical fracture, and 6 studies excluded patients with either existing
(“need of bone surgery” was interpreted as existing pathological
fracture) or impending pathological fracture. Three of the studies
excluded patients with pathological fracture speciﬁed the location of
fracture in the long bone, and 1 study followed Mirel's criteria for
measurement of impending fracture. Nine studies excluded patients
presenting with spinal cord compression, and 3 studies excluded
patients with either spinal cord or cauda equina compression. A total
of 18 studies excluded patients who received previous radiation
therapy, consisting of 17 studies which excluded patients who received
radiation to the same treatment site, and 1 study which excluded
patients who received any radiotherapy 10 weeks prior to the study.
4. Discussion
A systematic review showed that SF radiotherapy resulted in
equivalent pain relief to MF courses of radiation therapy for patients
with uncomplicated painful bone metastases [3]. However, in order
to apply the ﬁndings of this paper to the appropriate patient
population, a description for the term “uncomplicated bone metas-
tases” is preferred. Based upon an analysis of inclusion/exclusion
criteria for 21 prospective randomized studies, we suggest the
following working deﬁnition: uncomplicated bone metastases are
those unassociated with impending or existing pathologic fracture
or existing spinal cord compression or cauda equina compression.
The strengths of this deﬁnition are its simplicity and its
usefulness in translating existing data into daily practice. The
shortcomings of this deﬁnition include the lack of uniform criteria
to suggest an impending fracture as well as the variable deﬁnitions
of spinal cord compression or cauda equina compression.
Although 9 studies excluded patients with spinal cord compres-
sion alone, and 3 studies excluded patients with spinal cord
compression or cauda equina compression, none provided a
deﬁnition or associated symptoms of such conditions. Further-
more, only 4 studies by Roos et al. [19], Hartsell et al. [20], Safwat
et al. [23], and Foro Arnalot et al. [25] required clinical or
radiological evidence of compression. Still, in spite of these
nuances, the case can be made for conformity of treatment in
patients whose clinical circumstances reside within the conﬁnes of
this deﬁnition.
Table 1
Eligibility criteria for randomized controlled studies.
Study Inclusion criteria Exclusion criteria
Price [5]  Painful bone metastases
 Cytological or histological evidence of malignancy
 Prognosis less than 6 weeks
 incapable of completing the pain chart
 Pathological fracture of long bone
 Previous radiotherapy
 Change in systemic therapy within 6 weeks
Cole [6]  Metastatic bone pain
 Life expectancy of at least 3 months
 Spinal cord or peripheral nerve compression syndrome
 Actual or threatened pathological fracture
 Previous radiotherapy
Kagei [7]  Painful bone metastases  Treated with chemotherapy on same day as radiotherapy
 Fracture which was not vertebral compression fracture caused
by bone metastases
Gaze [8]  Histologically or cytologically proven cancer, and demonstrated
by plain radiography or skeletal scintigraphy
 Could be re-entered into the trial if separate, previously
untreated, painful areas
 Maximum ﬁeld size of 150 cm2 was allowed where spinal cord
or bowel was included in the ﬁeld, or 200 cm2 for more
peripheral sites
 Prior irradiation
 New concurrent systemic treatment
 Serious inter-current illness or life expectancy of o4 weeks
 Spinal cord compression, vertebral collapse above the level of
L2, impending or established pathological fracture, or prior
surgical ﬁxation
 Widespread disease requiring large-ﬁeld or hemi-body
irradiation
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Table 1 (continued )
Study Inclusion criteria Exclusion criteria
Nielsen [9]  Painful bone metastases localized to a single region that
previous radiotherapy to the region concerned could be
encompassed within a single radiation ﬁeld
 Histopathologically or cytologically conﬁrmed malignancy and
metastases were radiologically veriﬁed
 Able to complete a pain evaluation form
 Life expectancy more than 6 weeks
 Pathological fractures except compression fractures of the
vertebral spinal column
 Spinal cord compression
Foro [10]  Painful bony metastases
 Any primary tumor
 Pathological fractures
 Risk of fractures
 Medulla compression
 Requiring hemi-body irradiation
Koswig [11]  Histologically proven breast, lung, prostate and kidney
carcinoma
 Radiologically solitary osteolysis with or without fracture risk
and with pain
 Osteolytic lesion had to be suitable for bone density
measurements via CT
 Prior irradiation
 New systematic therapies in the last two weeks
BPTWP [12]  Histological or cytological diagnosis of cancer
 Age over 18 years
 pain
 Willingness to complete pain questionnaires for 12 months
 Pathological fracture of a long bone
 Previous radiotherapy
 Earlier entry into the same trial
Kirkbride [13]  Painful bone metastases from any primary tumour site and the
estimated survival was 44 months
Not available
Ozsaran [14]  Solitary or multiple bone metastases
 Cytological or histological evidence of malignancy
 Karnofsky performance status greater or equal to 50
 Allowed to re-enter the trial if they previously untreated painful
bone metastases
 Previous radiotherapy
 Prior surgical treatment for pathologic fracture or cord
compression
Sarkar [15]  Patient able to determine subjectively the amount of pain.
 Cytologically or histologically proven malignant disease with
painful bone metastases
 previous radiotherapy
 concurrent chemotherapy or hormone therapy
 chemotherapy within the last 4 weeks or hormone therapy
within the last 8 weeks
 Pathological fracture
Altundag [16]  Histological or pathological malignancy
 Painful bone metastases
 pain can be assessed/quantiﬁed
 prior radiation therapy
 surgical intervention
 Symptoms of spinal cord compression
 Pathological breaks
Badzio [17]  Cytological or histopathological evidence of cancer
 Conﬁrmed by X-ray
 Pathological fracture or previous irradiation to the
metastatic sites
van der Linden [18]  Painful bone metastases
 solid tumors
 Pain score minimum 2 on 11-point scale (0¼no pain to
10¼worst imaginable pain)
 Metastases treatable in one radiotherapy target volume
 Pathologic fracture or impending fracture needing surgical
ﬁxation
 Spinal cord compression
 Renal cell carcinoma or melanoma
 cervical spine
 Previous radiotherapy
Roos [19]  Pathologically conﬁrmed malignancy
 Plain X-ray or bone scan evidence of bone metastasis
 Pain or dysaesthesia predominantly of a neuropathic nature
 Life expectancy at least six weeks.
 Able to complete the pain assessments
 Metastasis within the distribution of the neuropathic pain (e.g.
shaft of femur metastasis with L2 neuropathic pain)
 Prior radiotherapy to the index site
 Clinical or radiological evidence of compression of the spinal
cord or cauda equina
 Pathological fracture of long bone(s) at index site
 Change in systemic therapy within 6 weeks before, or
anticipated within 4 weeks after commencing radiotherapy
 Neuropathic pain due primarily to extra-skeletal tumor
Hartsell [20]  Age of 18 years or older
 Histologically proven malignancy of breast and prostate
 Radiographic evidence of bone metastasis
 Painful bone metastasis
 A Karnofsky performance status of at least 40
 Life expectancy of at least 3 months
 Pain assessed with the Worst Pain Score from the Brief Pain
 Pathologic fracture or impending fracture of the treatment site
 Planned surgical ﬁxation of the bone
 Clinical or radiographic evidence of spinal cord or cauda equina
compression and/or effacement
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In contrast, the use of SF and MF radiation therapy treatments
vary in patients with complicated bone metastases. A randomized
controlled trial by Patchell et al. evaluating the efﬁcacy of direct
decompressive surgery showed that decompressive surgical resec-
tion and post-operative MF radiation therapy (30 Gy in 10 frac-
tions) combined is superior to radiation therapy alone for patients
with cord compression by metastatic cancer restricted to a single
area and fair to good motor function below the injury level [30].
Furthermore, MF (median dose 30 Gy) in postoperative radiation
therapy following stabilization of impending pathological fracture
was associated with increased functional status, decreased failure
of the prosthesis, and perhaps improved overall survival [31].
In another randomized trial by Maranzano et al., 8 Gy SF radiation
therapy was shown to be effective in achieving palliation
in patients with metastatic spinal cord compression by bone
metastases and poor performance status. However, this may be
Table 1 (continued )
Study Inclusion criteria Exclusion criteria
Inventory, requiring a score of at least 5 on a scale of 10 (or a
score of less than 5 but taking narcotic medications with a daily
oral morphine equivalent dose of at least 60 mg)
 Patient with up to 3 separate sites of painful metastases
 Patient receiving biphosphonates or systemic therapy
(hormonal therapy, chemotherapy, immunotherapy, or systemic
radioisotope therapy) as long as no introduction of any systemic
therapy within the 30 days before entry into the study
El-Shenshawy [21]  Painful bone metastases from a solid tumor
 Radiologically veriﬁed bony metastases
 Histopathologically or cytologically conﬁrmed malignancy
 Previous radiotherapy
 Pathological fractures except compression fractures of the
vertebral spinal column and suspicion of spinal cord
compression
 Chemotherapy and/or hormonal treatment was allowed but not
during radiotherapy, and all changes related to such treatment
were carefully registered
 New concurrent treatment
Hamouda [22]  Localized bone metastases
 Histological or cytological evidence of malignancy
 Radiographic evidence of bone metastasis
 No change in chemotherapy or hormonal therapy within
30 days
 Pathological fractures
 Previous radiotherapy
Safwat [23]  18 years or older
 Known malignancy metastatic to bone causing neuropathic pain
 Life expectancy of at least 3 months
 Clinical or radiological evidence of cord or cauda equina
compression
 irradiation or hormonal treatment, biphosphonates or
chemotherapy within 10 weeks prior to the study
Amouzegar-
Hashemi [24]
 Adult with painful uncomplicated bone metastases  Cord compression or existing or impending pathologic fracture
Foro Arnalot [25]  Age of 18 years or older
 Estimated life expectancy of at least 1 month
 Reported pain due to a pathological fracture or
 impending fracture following Mirels' criteria; patients with a
score of 9 were referred for prophylactic surgical ﬁxation
 Clinical or radiographic evidence of spinal cord compression
 Pain at more than one site
 Prior radiotherapy
 Pain could not be assessed either because of an overall poor
state of health or due to difﬁculties in applying the ordinal pain
scale (OS)
Steenland [26]  Painful bone metastases from solid tumor
 Pain score of at least 2 on 11-point scale at time of admission
 Bone metastases treatable in one target volume
 Karnofsky index of 60% or more
 previously irradiated
 Pathological fracture needing surgical ﬁxation
 Spinal cord compression
 Melanoma or renal cell carcinoma
 Cervical spine
Sande [27]  Biopsy- or cytology-proven malignancy and bone metastasis
veriﬁed either by bone X-ray, bone scan, CT or MRI
 Karnofsky performance status above 40
 Painful bone metastases
 Previous irradiation
 Spinal cord compression
 Need of bone surgery
 unable to complete the QOL assessment tools
 Life expectancy less than 6 weeks
Kaasa [28]  Painful bone metastases
 Biopsy-or cytology-proven malignancy, bone metastasis veriﬁed
by bone X-ray, bone scan, CT or MRI
 Karnofsky performance status above 40
 Previous irradiation
 spinal cord compression
 Need of bone surgery
 Unable to complete the QOL assessment tools
 Life expectancy less than 6 weeks
Haddad [29]  Adult with painful uncomplicated bone metastases  Cord compression or existing or impending pathologic fracture
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attributed to the short life expectancy (6 months or less) of
included patients, who would beneﬁt from minimal toxicity and
convenience of SF [32]. Moreover, a study by Roos et al. comparing
SF and MF in patients with bone metastases presenting with
neuropathic pain suggested SF was not as effective as MF in
treating neuropathic pain, although it was not statistically sig-
niﬁcantly worse [19].
It is important to recognize that our deﬁnition of uncompli-
cated bone metastases may be incomplete. Only 2 of the 21 studies
in the updated review excluded patients presenting with neuro-
pathic pain, a common complication of bone metastases. There-
fore, we could not incorporate the absence of neuropathic pain
into our deﬁnition. Furthermore, bone metastases with soft tissue
mass were not excluded in any of the studies examined. As such,
the absence of a soft tissue mass cannot be considered a char-
acteristic of uncomplicated bone metastases. Only 1 study veriﬁed
bone metastases through 3D imaging such as CT or MRI, and 12
studies did not require any radiographic evidence. Therefore,
interpreting results of older studies should consider the lack of
reliable radiographic evidence. Future trials may beneﬁt from
examining the bone metastases with soft tissue masses for a dose
response phenomenon.
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